Novartis heart failure drug should have 17 percent discount: analysis

September 11, 2015 5:55 PM

23 0

Novartis heart failure drug should have 17 percent discount: analysis

A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER.

In a draft report released on Friday, the Boston-based Institute for Clinical and Economic Review set its "value-based" price for Entresto at $3,799 annually. The independent ICER evaluates clinical and cost effectiveness of new medicines.

Also read: Eurowings settles pay dispute with airline cabin crew

Read more

To category page

Loading...